



SEMPERIT GROUP H1 2022 INVESTOR PRESENTATION

Karl Haider, CEO

Petra Preining, CFO

17 August 2022



Agenda

Key Highlights (p.2)

Operational Performance (p.6)

Financial Performance & Strategy (p.14)

Outlook (p.24)

Appendix (p.27)



Operational highlights H1 2022



Strong H1'22 results despite geopolitical challenges; outstanding Industrial performance while Corona induced special cycle in Medical Sector has come to an end



Industrial Sector in H1'22 well above H1'21: still healthy sales volumes and order book levels despite input price headwinds



Medical Sector prices reverted towards pre-Corona level, with massive inventory build-up in 2021 continuing to result in lower demand in the market



Exogenous operational issues such as high gas prices (and potentially limited availability) under control through proactive management action on supply chains, raw materials and alternative energy supply



Strategy update: major organic growth investment of € 110m into the world's first carbon-neutral hose production facilities at Semperflex; US plant inaugurated in Q2'22 at Semperséal – alongside ongoing M&A activities





Step up in organic growth: € 110m for Semperflex's DH5 (1)

World's first carbon-neutral hose production facilities




Production capacity to be increased by **32m meters** of hydraulic hose to **almost 200m meters** of hose in total per year



Significant increase in market- and supply-share and **continued growth** above the market average

CAPEX "front loaded" between 2023 and 2027



Operation starts in early 2025 with **16m meters, full capacity** to be reached **step by step by 2028**
– CAPEX "front loaded" between 2023 and 2027



#3
of the world



Step up in organic growth: € 110m for Semperflex's DH5 (2)

World's first carbon-neutral hose production facilities



Being located close to European customers results in **more manageable supply chains, faster deliveries, reduced carbon emissions, and cheaper transportation**



Hose production will be **powered exclusively by renewable energy**; overall water consumption at the plant in Odry will **decrease by ~30%**



Increased level of automation leads to **productivity gains and higher quality**



Production requiring less FTEs while more **gender neutral**



Successful strategic set-up for Semperflex to scale up



Stand-alone new production facility **strongly expands EBITDA margin leadership**





Agenda

Key Highlights (p.2)

Operational Performance (p.6)

Financial Performance & Strategy (p.14)


Outlook (p.24)

Appendix (p.27)




Outstanding industrial sector performance with continuing top-line growth

Revenues in EUR m
H1'19 –H1'22



Quarterly development of EBITDA (in EURm) and EBITDA margin (in%)




- Revenues increased by 39%, EBITDA up by 64% yoy – proactive margin management
- Strong improvement from Q1 to Q2 2022 due to high demand and price increases at Semperfex combined with previous management attention for Sempertrans paying off
- Exceptionally high inflation and energy prices add to existing margin pressure from high raw materials and logistics costs - more pressure expected in H2'2022 which might impact sales volumes
- Customers focus on working capital expected to be increased (inventory reductions)




Semperflex H1 2022

Consistently improving performance

Semperflex



H1 2022 vs. H1 2021



- Sales up by 52% yoy and EBITDA by 78% yoy due to both price increases following higher input costs as well as higher volumes and efficiency gains (economies of scale)
- Strong operating performance with consistently improving margins
- Systematic processing of a historically high order book resulting in lower absolute volumes going forward
- Growth CAPEX: EUR 110m assigned to Odry DH5








Sempertrans H1 2022

Systematic recovery evident in results

Sempertrans



H1 2022 vs. H1 2021



- Demand from mining industry remains positive due to higher commodity prices – specifically implying big replacement projects
- Order book at highest level in more than three years
- Improved top line and profitability, despite partial delays in sales realisation due to tight logistics
- Positive margin development – due to partial sales price increases



¹ Q1'19 EBITDA: positive effects of € 1.3m profit from sale of assets of closed factory in China



² Q3'21 EBITDA: positive effect of € 3.7m from recycling of foreign exchange differences




Sempers seal H1 2022

Difficult market limits pricing power and cost recovery


Sempers seal



H1 2022 vs. H1 2021



- Good order intake, order book above H1'21
- Top line improvement in line with pricing strategy
- Volumes impacted by discontinuation of Russian sales activities
- USA: ramp up of first production line in Newnan, (Georgia) at new production site in Q1'22 – followed by the second line in early Q3'22







Semperform H1 2022

Margin resilience due to product mix

Semperform



H1 2022 vs. H1 2021



- Historically strong order intake supports top-line growth
- Strong turnover with price increases to offset cost inflation ensure stable profitability / margins yoy
- BU Handrails stable yoy while BU Special Applications see higher and BU Engineered Solutions lower demand
- Negative impact of China lockdown offset by global handrail business in Q2'22







Medical Sector / Sempermed segment H1 2022

Reversal from overheated 2021 to “new normal” 2023

Sempermed



H1 2022 vs. H1 2021



- Corona-induced special cycle came to an end
- Market overstocked – affecting all producers: reversal from excessive stock piling in 2021 to a more normalised 2023
- Margins under pressure: Strong increase of raw materials and gas prices, inflation strongly impacting personnel costs
- Order book still above pre-corona level



¹ Q3'19 EBITDA adjusted for € 4m due to the positive effect from the release of provision in Sempermed for Brazilian court case for tax liabilities



Semperit's response to the current energy crisis



Tense energy situation intensified over the years due to climate changes has now accelerated through Russian war in Ukraine and resulting supply constraints



The “30 by 2030” initiative as part of the ESG strategy focuses among others on **energy efficiency improvements** and implies several measures to reduce Semperit's energy consumption step by step



Energy reduction measures are **continuously revisited** and **newly prioritised** based on current developments (incorporating energy and economical aspects) thus providing flexibility and strategy adaption



Alternatives for gas burners have been or are currently being planned and installed at European sites (Austria, Czech Republic and Germany) to guarantee ongoing production in case of gas delivery stops – with additional options for securing alternative energy supplies



Agenda

Key Highlights (p.2)

Operational Performance (p.6)

Financial Performance & Strategy (p.14)

Outlook (p.24)

Appendix (p.27)



H1 2022 Financial Highlights



Outstanding industrial performance against adverse exogenous market shocks while Covid-related special cycle ends in Medical Sector



Proactive working capital management remains key focus area as cost inflation and inventory build-up continue



Special attention paid to ensuring stability, quality of order book and protecting margins through proactive pricing policy and cost reduction measures



Focus on cash management and US-dollar investments given strong USD



Strong balance sheet maintained despite cash outflow for investments, dividend and repayments of debt and headwinds in the Industrial Sector during the last two years




Outlook confirmed given strong signs of economic downturn (upcoming recession, energy price and availability, geopolitical impacts on supply chain)





Revenue development




% change of each segment / sector refers to 2022 vs. 2021.



Strong performance in Industrial more than offset by disproportionate decline in Medical


in € m



	H1 2021	Semperflex	Sempertrans	Semperseal	Semperform	Sempermed	Corporate	H1 2022
EBITDA H1 2021	247.5	26.2	1.8	6.6	6.6	220.5	-14.3	
EBITDA H1 2022		46.8	6.6	6.2	8.2	15.6	-8.3	75.1
EBITDA margin H1 2022		27.0%	9.5%	8.3%	15.4%	7.9%	–	13.2%



Major drivers of operating performance



in € million



Overview of key financial KPIs, H1 2019 – H1 2022

	H1 2019	H1 2020	H1 2021	H1 2022	ΔH1'19/22
EBITDA, in € m	39.1	57.6	247.5	75.1	↗ +92%
EBITDA margin, in %	9.0	13.7	37.5	13.2	↗ +4.2PP
EBIT, in € m	20.9	112.2	224.6	48.3	↗ +132%
EBIT margin, in %	4.8	26.8	34.0	8.5	↗ +3.7PP
Earnings after tax, in € m	5.8	101.7	173.9	35.6	↗ +497%
Free Cashflow, in € m	39.8	47.1	166.9	- 4.6	↘ n.m.
CAPEX, in € m	21.4	11.9	18.8	28.4	↗ +32%




Quarterly CAPEX development 2021-2022

- Continued healthy level of CAPEX
- Outlook 2022: planned to be above 2021 level
- Industrial Sector: increasing focus on growth CAPEX

CAPEX per segment


in € m





Free cash flow development

- Reduced operating cash flow due to reversal of Covid-related special cycle in Medical Sector
- Pre tax operating cash flow impacted by proactive inventory build up
- Investment cash flow driven by increased CAPEX level



- Pre-tax operating cash flow
- Investment cash flow
- Free cash flow (adjusted)

Free cash flow adjusted:

Operating cash flow adjusted for tax payments (H1 2020: € 6m; H1 2021: € 16m, H1 2022: € 32m)


Investment cash flow H1 2021 adjusted for investments in money market funds shares (€ -50m)



Working Capital overview

Components of Working Capital

in € m




¹ Trade Working Capital in % of LTM revenues



Balance sheet structure and financial profile

Balance sheet structure

Balance sheet 30/06/2022: € 970m
Balance sheet 31/12/2021: € 959m



Financial profile as of 30 June 2022

- **Cash and cash equivalents** at € 193m
- **Unused credit facilities** total € 90m
- **Corporate Schuldschein loan** at € 87m
- payment of € 34m in July as planned
- **“Net debt” remains net cash** at € 106m,
Net debt / EBITDA below zero (YE'21: below zero)
- **Equity ratio** of 57.4% (YE'21: 56.3%)
- **Dividend** of EUR 1.50 for 2021 paid in May 2022



Agenda

Key Highlights (p.2)

Operational Performance (p.6)

Financial Performance & Strategy (p.14)

Outlook (p.24)

Appendix (p.27)



Management assumptions for 2022



Starting Point H1'22

**Outstanding results in Industrial Sector
.... BUT...**

**accelerated
in H1'22**

Geopolitical crises

Continuing supply constraints and reduced components availability

Energy crisis in Europe, cost inflation, FX, working capital

Expectations for H2 2022

**Seasonally weaker H2, scheduled maintenance stops, contracting economic activity;
Medical Sector: pressure from reversal of excessive stock piling, uncertainty of normalisation**

European energy crisis to be mitigated through installed alternatives to gas burners to alleviate gas supply constraints

High uncertainty regarding energy, geopolitical situation and negative effects of inflation, FX and supply chains

**Market dynamics likely to deviate from current supply & demand assumptions
– with cost inflation accelerating throughout the industry and growth slowing down further**

Outlook confirmed as published in March given strong signs of economic downturn





Contact and financial calendar

Investor Relations Semperit

Judit Helenyi, Director Investor Relations

+43 1 79777 - 310

www.semperitgroup.com/en/ir

Am Belvedere 10

1100 Vienna, Austria

Financial Calendar 2022

17.8.2022 Half-year financial report 2022

16.11.2022 Report on Q1-3 2022

Disclaimer

The information provided in this presentation does not constitute an offer for the sale of securities nor an invitation to submit an offer to purchase shares of Semperit AG Holding, but exclusively serves information purposes.

The terms “Semperit” or “Semperit Group” in this presentation refer to the group; “Semperit AG Holding” or “Semperit Aktiengesellschaft Holding” is used to refer to the parent company (individual company).

We have prepared this presentation and verified the information it contains with the greatest possible care. Nevertheless, rounding, typesetting and printing errors cannot be ruled out. Rounding of differences in the summation rounded amounts and percentages may arise from the automatic processing of data.

The forecasts, plans and forward-looking statements contained in this presentation are based on the knowledge and information available and the assessments made at the time that this presentation was prepared. As is true of all forward-looking statements, these statements are subject to risk and uncertainties. As a result, actual events may deviate significantly from these expectations. No liability whatsoever is assumed for the accuracy of projections or for the achievement of planned targets or for any other forward-looking statements. Words such as “expect,” “want”, “believe,” “anticipate,” “includes,” “plan,” “assumes,” “estimate,” “projects,” “intends,” “should,” “will,” “shall,” or variations of such words are generally part of forward-looking statements.

Furthermore, there is no guarantee that the contents are complete. Statements referring to people are valid for both men and women.



Agenda

Key Highlights (p.2)

Operational Performance (p.6)

Financial Performance & Strategy (p.14)

Outlook (p.24)

Appendix (p.27)



Sectors and Group: Q1 2022 vs Q1 2021

in EUR m	Industrial Sector			Medical Sector			Semperit Group		
	H1 2022	H1 2021	%	H1 2022	H1 2021	%	H1 2022	H1 2021	%
Revenue	372.3	268.1	+38.9%	198.3	392.7	-49.5%	570.6	660.8	-13.6%
EBITDA	68.0	41.3	+64.4%	15.6	220.5	-92.9%	75.2	247.5	-69.6%
EBITDA margin	18.3%	15.4%	+2.8 PP	7.9%	56.2%	-48.3 PP	13.2%	37.5%	-24.3 PP
EBIT	54.5	29.0	+88.0%	2.9	210.6	-98.6%	48.4	224.6	-78.5%
EBIT margin	14.6%	10.8%	+3.8 PP	1.5%	53.6%	-52.2 PP	8.5%	34.0%	-25.5 PP
Earnings after tax	-	-	-	-	-	-	34.7	173.9	-80.0%
Earnings per share in EUR	-	-	-	-	-	-	1.7	8.4	-80.0%
Additions in tangible and intangible assets	9.6	11.6	-17.6%	9.2	9.8	-6.4%	20.3	22.0	-7.9%
Employees	3,892	3,615	+7.7%	2,969	3,198	-7.2%	6,936	6,956	-0.3%

Figures of Semperit Group also contain intercompany consolidation and the results of the Corporate Segment




Semperit Group adj. where applicable


Semperit Group adj. where applicable

in EUR m	FY 2019	Q1 2020	Q2 2020 adj. ¹⁾	Q3 2020 adj. ²⁾	Q4 2020 adj.	FY 2020 adj. ³⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022
Revenue	840.6	199.1	219.8	238.2	270.5	927.6	323.1	337.7	265.3	256.1	1,182.2	277.0	293.6
EBITDA	63.8	16.9	40.7	60.9	90.0	208.6	122.2	125.3	76.8	37.5	361.8	36.5	38.7
EBITDA margin	7.6%	8.5%	18.5%	25.6%	33.3%	22.5%	37.8%	37.1%	28.9%	14.6%	30.6%	13.2%	13.2%
EBIT	28.2	9.8	33.6	49.2	78.8	171.4	110.8	113.8	65.4	25.0	315.0	23.7	24.7
EBIT margin	3.4%	4.9%	15.3%	20.7%	29.1%	18.5%	34.3%	33.7%	24.7%	9.8%	26.6%	8.6%	8.4%

EBITDA adj. per quarter



EBIT adj. per quarter



¹⁾ Q2 2020: adjusted for the positive one-off effect from the write-up in the Sempermed segment (EBIT: EUR 88.8 million) and the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect –20.0 Million EUR) ²⁾ Q3 2020: adjusted for the special effect from the write-up in the Sempermed segment (EBIT: EUR –2.1 million) and the special effect from the impairment in the Sempertrans segment (EBIT effect EUR +0.1 million). ³⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR –19.8 million)



Semperflex and Sempertrans (adj. where applicable)

Semperflex (Hoses)

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022
Revenue	61.1	59.7	53.8	48.0	222.7	46.8	51.5	46.6	45.0	189.9	54.7	59.7	57.7	68.4	240.5	79.8	93.9
EBITDA	13.9	14.5	10.8	8.7	47.9	9.3	14.0	11.4	7.2	41.9	12.3	13.9	11.2	13.9	51.3	19.6	27.3
EBITDA margin	22.8%	24.3%	20.1%	18.1%	21.5%	19.9%	27.2%	24.5%	16.0%	22.1%	22.5%	23.3%	19.3%	20.4%	21.3%	24.5%	29.0%
EBIT	11.1	11.5	7.7	5.7	36.0	6.5	11.2	8.7	4.5	30.9	9.6	11.1	8.4	11.0	40.0	16.6	24.3
EBIT margin	18.2%	19.2%	14.3%	11.9%	16.2%	13.9%	21.8%	18.6%	10.0%	16.3%	17.5%	18.5%	14.5%	16.1%	16.6%	20.8%	25.8%

Sempertrans (Conveyor belts)

in EUR m	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020 adj. ¹⁾	Q3 2020 adj. ²⁾	Q4 2020 ³⁾	FY 2020 adj. ⁴⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022
Revenue	30.4	37.8	35.1	30.6	134.0	29.5	32.5	28.4	22.7	113.1	26.9	24.2	28.0	25.3	104.5	28.3	41.5
EBITDA	2.7	5.4	4.6	0.8	13.5	1.6	5.0	2.1	0.0	8.7	1.0	0.8	4.7	0.4	6.8	1.3	5.3
EBITDA margin	9.0%	14.2%	13.1%	2.5%	10.1%	5.4%	15.4%	7.6%	0.0%	7.7%	3.8%	3.3%	16.7%	1.4%	6.6%	4.5%	12.9%
EBIT	1.8	3.8	3.6	-0.3	8.9	0.6	3.9	1.4	-0.6	4.9	0.2	-0.1	3.8	-0.7	3.2	0.3	4.4
EBIT margin	6.0%	10.0%	10.4%	-0.9%	6.7%	1.9%	11.9%	5.0%	-2.6%	4.3%	0.7%	-0.2%	13.6%	-2.9%	3.1%	1.2%	10.5%

¹⁾ Q2 2020: adjusted for the negative one-off effect from the impairment in the Sempertrans segment (EBIT effect: EUR 20.0 million).

²⁾ Q3 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

³⁾ Q4 2020: adjusted for the special effect of the impairment in the Sempertrans segment (EBIT effect: EUR +0.1 million)

⁴⁾ 2020: Adjusted for the negative one-off effect of the impairment in the Sempertrans segment (2020 EBIT effect: EUR 19.8 million)



Semperform and Semperséal (adj. where applicable)

Semperform (Window and door profiles, Handrails) - before 2020										
	FY 2017 adj.	Q1 2018	Q2 2018	Q3 2018	FY 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019
in EUR m										
Revenue	185.0	47.5	50.7	50.3	192.2	49.9	50.5	47.8	42.4	190.6
EBITDA	21.5	4.5	7.3	6.2	21.9	7.9	8.3	6.6	3.3	26.0
EBITDA margin	11.6%	9.6%	14.4%	12.2%	11.4%	15.7%	16.4%	13.8%	7.8%	13.6%
EBIT	13.3	2.4	5.1	4.2	13.2	5.4	5.9	4.2	0.5	16.0
EBIT margin	7.2%	5.0%	10.1%	8.4%	6.9%	10.9%	11.6%	8.7%	1.1%	8.4%

Semperform (Window and door profiles, Handrails) - after 2020																	
	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022
in EUR m																	
Revenue	22.4	24.6	22.3	21.8	91.1	19.9	21.9	20.4	19.6	81.8	19.8	23.6	23.3	23.9	90.6	26.2	27.5
EBITDA	4.0	4.8	4.1	2.7	15.6	3.5	5.0	4.0	2.5	15.0	3.1	3.6	3.3	2.5	12.4	3.2	5.0
EBITDA margin	17.7%	19.6%	18.4%	12.2%	17.1%	17.5%	22.6%	19.6%	12.9%	18.3%	15.4%	15.2%	14.1%	10.3%	13.7%	12.2%	18.3%
EBIT	3.1	4.0	3.2	1.7	12.0	2.6	4.1	3.1	1.6	11.3	2.1	2.6	2.3	1.4	8.5	2.1	4.0
EBIT margin	13.9%	16.1%	14.3%	7.7%	13.1%	12.9%	18.5%	15.1%	8.0%	13.8%	10.8%	11.2%	10.0%	6.0%	9.4%	8.2%	14.4%

Semperséal (Profiles and Rubber Sheeting) starting in 2020																	
	Q1 2019	Q2 2019	Q3 2019	Q4 2019	FY 2019	Q1 2020	Q2 2020	Q3 2020	Q4 2020	FY 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022
in EUR m																	
Revenue	27.5	25.8	25.6	20.5	99.5	25.4	21.7	24.4	22.2	93.6	28.7	30.3	32.4	29.1	120.5	36.6	38.4
EBITDA	3.9	3.4	2.5	0.6	10.4	3.3	3.2	2.9	1.7	11.0	4.2	2.4	4.1	0.9	11.6	2.4	3.9
EBITDA margin	14.1%	13.2%	9.8%	3.0%	10.5%	12.8%	14.7%	12.0%	7.5%	11.8%	14.7%	7.9%	12.6%	3.0%	9.6%	6.5%	10.1%
EBIT	2.3	1.9	1.0	-1.2	4.0	1.8	1.7	1.4	0.2	5.1	2.6	0.8	2.5	-0.9	5.1	0.5	2.3
EBIT margin	8.4%	7.3%	3.9%	-5.8%	4.0%	6.9%	8.0%	5.8%	1.1%	5.5%	9.2%	2.6%	7.7%	-3.1%	4.2%	1.4%	5.9%

Split of former Semperform into Semperséal and Semperform as of 1st January 2020 – historic Semperform numbers for 2019 adapted for this split accordingly



Sempermed (adj. where applicable)

Sempermed (Gloves)

	Q1 2019	Q2 2019	Q3 2019 adj. ¹⁾	Q4 2019	FY 2019 ²⁾	Q1 2020	Q2 2020 adj. ³⁾	Q3 2020 adj. ⁴⁾	Q4 2020 ⁵⁾	FY 2020 adj. ⁶⁾	Q1 2021	Q2 2021	Q3 2021	Q4 2021	FY 2021	Q1 2022	Q2 2022
in EUR m																	
Revenue	71.5	76.4	78.2	67.3	293.3	77.5	92.2	118.4	161.1	449.2	192.9	199.8	124.0	109.4	626.1	106.1	92.3
EBITDA	-0.9	0.6	1.8	-0.1	1.4	4.8	18.2	44.4	83.0	150.4	105.3	115.3	56.9	23.7	301.1	13.3	2.3
EBITDA margin	-1.2%	0.8%	2.3%	-0.1%	0.5%	6.1%	19.7%	37.5%	51.5%	33.5%	54.6%	57.7%	45.9%	21.7%	48.1%	12.6%	2.5%
EBIT	-2.8	-1.4	-0.3	-0.9	-5.5	4.4	17.6	38.9	77.8	138.7	100.2	110.3	52.1	18.3	280.9	7.6	-4.7
EBIT margin	-3.9%	-1.9%	-0.4%	-1.4%	-1.9%	5.5%	19.1%	32.8%	48.3%	30.9%	52.0%	55.2%	42.0%	16.7%	44.9%	7.2%	-5.1%

¹⁾ Q3 2019 adjusted for negative one-off effect of EUR 46.8 million from impairment of Sempermed (adj. for EBIT) and EUR 4 million (EBITDA, EBIT) due to release of provision in Sempermed for Brazilian court case for tax liabilities.

²⁾ 2019: adjusted for the positive one-off effect from the reversal of a provision for the tax procedure on levies in Brazil (EBITDA, EBIT: EUR 4.0 million), as well as the negative effect of the impairments for the Sempermed segment (EBIT: -48.8 million EUR)

³⁾ Q2 2020: adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT: EUR +88.8 million)

⁴⁾ Q3 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -2.1 million)

⁵⁾ Q4 2020: adjusted for the special effect of the write-up in the Sempermed segment (EBIT effect: EUR -0.5 million)

⁶⁾ 2020: adjusted for the positive one-off effect of the reversal of impairment in the Sempermed segment (2020 EBIT effect: EUR +86.2 million)



Key figures 2011-2021

Key performance figures											
in EUR m	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016 adj. ⁴⁾	2017 adj. ⁵⁾	2018 adj. ⁶⁾	2019 adj. ⁷⁾	2020 adj. ⁸⁾	2021
Revenue	820.0	828.6	906.3	858.3	914.7	852.4	874.2	878.5	840.6	927.6	1,182.2
EBITDA	110.0	108.7	132.5	101.9	96.2	74.7	35.8	50.3	63.8	208.6	361.8
EBITDA margin	13.4%	13.1%	14.6%	11.9%	10.5%	8.8%	4.1%	5.7%	7.6%	22.5%	30.6%
EBIT	80.4	72.5	87.8	63.8	66.7	41.1	-0.8	15.4	28.2	171.4	315.0
EBIT margin	9.8%	8.8%	9.7%	7.4%	7.3%	4.8%	-0.1%	1.7%	3.6%	18.5%	26.6%
Earnings after tax	51.8	46.2	54.9	37.8	46.4	15.2	-43.9	-17.3	-0.2	121.9	247.5
EPS²⁾, in EUR	2.52	2.25	2.65	1.85	2.26	0.74	-2.08	-1.06	-0.33	5.53	11.99
Gross cash flow	89.4	85.6	116.2	89.9	55.7	48.1	32.2	37.4	46.70	193.7	323.4
Return on equity	13.6%	11.4%	13.3%	8.6%	12.8%	4.6%	-15.8%	-4.2%	-16.3%	58.0%	45.7%


Balance sheet key figures											
in EUR m	2011 ¹⁾	2012	2013	2014 ³⁾	2015 ³⁾	2016	2017	2018	2019	2020	2021
Balance sheet total	616.7	824.5	852.1	826.3	937.8	1034.5	853.2	768.8	701.8	764.4	958.6
Equity²⁾	379.4	406.2	411.5	443.8	363.3	329.3	278.5	329.5	237.4	332.3	540.1
Equity ratio	61.5%	49.3%	48.3%	53.7%	38.7%	31.8%	32.6%	42.9%	39.0%	43.5%	56.3%
Investments in tangible and intangible assets	45.1	41.2	49.7	67.4	71.8	65.1	74.5	80.8	31.9	26.4	47.9
Employees, at balance sheet date, FTEs	8,025	9,577	10,276	6,888	7,053	6,974	6,838	6,773	6,902	6,943	6,948

¹⁾ 2011 restated (see Annual Report 2012, Notes 2.18). ²⁾ 2014 and 2015 restated. ³⁾ 2016 without profit contribution from SSC / Thai glove JV, impairment Sempermed and trade tax / levies in Brazil. ⁴⁾ 2017 adjusted for positive one-off effects from JV transaction of € 85m (€ 65m for net profit) and negative one-off effects from impairment at Sempermed (€ 26m adj. EBIT, EAT only), from restructuring expenses in France (€ 11m), valuation adjustment in IT (€ 4m EBITDA, € 3m EBIT) and expenses resulting from tax audit in Austria (€ 5m, mainly for refund of energy supply charge). ⁵⁾ 2018 adjusted for negative one-off effects from closure of Sempertrans site in China (€ 4m for EBITDA, € 8m for EBIT and EAT) and for impairment of Sempermed of € 55m (adj. for EBIT and EAT only). ⁶⁾ FY 2019 adjusted for positive one-off effects of € 4m (EBITDA, EBIT, EAT) due to release of provision in Sempermed for Brazilian court case for tax liabilities and for negative one-off effects of € 48.8m from impairment at Sempermed from impairment of Sempermed (adj. for EBIT and EAT). ⁷⁾ 2020 adjusted for the positive one-off effect from the reversal of impairment in the Sempermed segment (EBIT effect: +86.2 million EUR; earnings after tax effect: +88.8 million EUR) and for the negative one-off effect of the impairment in the Sempertrans segment (EBIT effect EUR -19.8 million; earnings after taxes effect: EUR -16.1 million)



Overview price indices Butadiene

Price movements for raw materials¹⁾ became highly unpredictable




¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Overview price indices LFO-F-NWE / wire rod


Significant increase for raw material¹⁾ used in industrial segments

Price index LFO-F-NWE



— Fuel Oil 1% Sulphur NWE FOB Cargo

Price index wire rod



— Price index wire rod (Germany)

¹⁾ Selected raw materials are shown for illustration purposes only. Indices based on 01/01/2019 = 100.0



Product / market position / segment overview, FY 2021

in EUR m

Semperit Group

Group	Industrial Sector				Medical Sector	
	Semperflex	Sempertrans	Semperform	Semperseal	Sempermed	
Revenue	1.182.2	240.5 / 20% ¹⁾	104.5 / 9% ¹⁾	90.6 / 8% ¹⁾	120.5 / 10% ¹⁾	626.1 / 53% ¹⁾
EBITDA	361.8 ²⁾	51.3	6.8	12.4	11.6	301.1
Employees	6,948 ²⁾	1,753 / 25% ³⁾	921 / 13% ³⁾	576 / 8% ³⁾	514 / 7% ³⁾	3,038 / 44% ³⁾

Products and market position

Hydraulic hoses

3 position globally / leader in hose only



Industrial hoses

2 - 3 position in Europe
6 position globally



Conveyor belts

One of the leading suppliers of heavy-duty steel cord and textile conveyor belts



HSA* / SES**

Leading European manufacturers of moulded and extrusion products made of polymer and plastics
(**handrails, cable car rings, ski foils and Engineered Solutions**)



Profiles / Rubber Sheeting

Leading European manufacturer of sealing profiles and elastomer sheeting
(**construction, packaging, machinery, HVAC, marine, electric systems**)



Examination gloves

Among the top 15 glovemakers in the world



Surgical gloves

Among the leading companies in Europe




*Handrails, Special Applications
** Semperit Engineered Solutions

¹⁾ Revenue in % of Group revenue.
²⁾ Group figure includes corporate center of € -21m, 147 employees.
³⁾ Employees in % of Group employees.



Shareholder Structure

Shareholder structure



- Semperit is listed on the Vienna Stock Exchange since 1890
- Total of 20,573,434 shares
- B & C Holding Österreich GmbH is part of B & C Privatstiftung, an Austrian based private foundation / trust
- Primary focus of B & C is pursuing the foundation's mission to "foster Austrian entrepreneurship"
- Semperit benefits from a supportive ownership structure with long-term commitment from B & C